3rd ANZ Biologics Festival 2025

Australia and New Zealand's Only Conference on Biologics: From Discovery to Delivery

5th -

6th

February 2025 |

Melbourne, Australia

📆 Add to Google Calendar

Attendees

0 +

Companies

0 +

Speakers

0 +

In-Person Networking Hours

0 +

Case Studies

0 +

Concept

Excellence in Biologics Manufacturing, Cell and Gene Therapy, and RNA Therapeutics for Australia & New Zealand's Future Biologics Industry

With a biotechnology sector benchmarked for global excellence due to world-class facilities, researchers, and regulation, the ANZ region has a promising future for biologics innovation and manufacturing. The path ahead will require a focus on further commercial translation of research, and as such, partnerships and collaborations will be critical. Expanding sovereign manufacturing in Australia & New Zealand will also play a massive role in uplifting the sector in the region.

The 3rd ANZ Biologics Festival 2025 is the region's premier conference that aims to gather the innovators, pioneers, and leaders in the biologics fraternity, including Biologics, Biosimilars, Vaccines, Cell and Gene Therapy (CGT), and RNA Therapeutics, to showcase the latest from ideation to commercialization phase and beyond. It provides the right environment to meet the entire biopharma fraternity under one roof.

Join us to bring investment to Australia & New Zealand's bio sector and explore a wealth of opportunities in biologics innovation, expanding the region's manufacturing footprint, and advancing cell and gene therapy and RNA therapeutics. The 2025 festival will feature dedicated tracks on Biologics Manufacturing, Cell and Gene Therapy, and RNA Therapeutics, offering a comprehensive view of the latest advancements and challenges in these critical areas.

FEATURED CONTENT

ABF24: Investing in New Zealand Biopharma

ABF24: Biologics Manufacturing Landscape in Australia

ABF24: Cell & Gene Therapy in ANZ

ABF24 Speaker Interview: Key Trends in the ANZ Biopharma Industry

ABF24: Overview of the Australia Biologics Industry

Quick look at ABF 2024: Australia & NZ Biopharma Industry Map

ABF23_Ebook-cover-1500-x-1500-1-1024x1024

ABF23 Speaker Interview Part 2: Key Future Trends & Innovations in the Australian Biopharma Industry

ABF23 Speaker Interview: Key Future Trends & Innovations in the Australian Biopharma Industry 2023

Quick Look at ABF 2025: ANZ Biopharma Industry Survey Focus Areas

[NEW] Quick Look at ABF 2025: Australia & NZ Biopharma Industry Map

[NEW] Quick Look at ABF 2025: ANZ CDMO Industry Map

[NEW] 2025 ANZ Biologics Advancements: A Comprehensive Overview

3rd ANZ Biologics Festival 2025

Current And Future State of the ANZ Biologics Market: An overview and forecast of trends, challenges, and opportunities in the biologics market in Australia and New Zealand.
Upstream Processing – Process Optimization & Intensification: Strategies and advancements in optimizing and intensifying the initial stages of biologics production to enhance efficiency and productivity.
Downstream Processing – Purification & Recovery for Better Product Efficiency & Yield: Techniques and innovations in purifying and recovering biologics to improve product quality and yield.
GMP Manufacturing, Analytics & Quality Control: Best practices and technologies for ensuring Good Manufacturing Practices (GMP), precise analytics, and rigorous quality control in biologics production.
Bioprocessing 4.0: Digitalization, AI, and Machine Learning for Manufacturing Efficiencies: Examining how digitalization, AI, and machine learning technologies are revolutionizing manufacturing processes to enhance efficiency and productivity in bioprocessing.
Designing & Executing Clinical Trials in the ANZ Region – Lessons Learnt: Sharing insights and experiences from designing and conducting clinical trials in Australia and New Zealand, highlighting key takeaways and best practices.
Biopharma Case Studies from ANZ Region: Presenting real-world case studies from biopharma companies in the ANZ region, showcasing successful strategies and innovations in biologics development.
Supply-Chain Management & Temperature Controlled Logistics: Discussing strategies and solutions for effective supply-chain management and maintaining temperature control in the logistics of biologics to ensure product integrity and quality

Current & Future Prospects for Cell & Gene Therapies in ANZ: Exploring the present landscape and future opportunities for cell and gene therapies in Australia and New Zealand, including regulatory and market trends.
Translational Strategy for Pre-Clinical and Clinical Programs: Discussing strategies to effectively transition therapies from pre-clinical research to clinical development, ensuring successful translation of scientific discoveries into clinical applications.
Building a Global Clinical Trial for Cell & Gene Therapies: Highlighting the challenges and best practices for designing and executing international clinical trials for cell and gene therapies, with a focus on regulatory and logistical considerations.
CGT Manufacturing Innovations for Safe, Efficient, and Scalable Therapies: Presenting cutting-edge manufacturing techniques and innovations that enhance the safety, efficiency, and scalability of cell and gene therapies.
Case Studies: Promising CGT Therapies from ANZ: Showcasing successful case studies of innovative cell and gene therapies developed in the ANZ region, highlighting clinical outcomes and potential impact.

Growing RNA Research & Manufacturing Capability in the ANZ Region: Discussing the expansion and advancements in RNA research and manufacturing capabilities within Australia and New Zealand, focusing on infrastructure and technological developments.
Accelerating Vaccine Manufacture with mRNA Technology: Exploring how mRNA technology is revolutionizing vaccine development and manufacturing processes, enabling faster and more efficient production.
Optimizing Delivery Platforms for Next Gen RNA Therapeutics: Examining advanced delivery systems and technologies designed to enhance the efficacy and safety of next-generation RNA-based therapeutics.
Case Studies: Breakthrough RNA Therapies from ANZ: Showcasing successful RNA therapies developed in the ANZ region, highlighting their innovative approaches and clinical outcomes.

To stay informed about event updates, including date, venue, and agenda, please subscribe to our newsletter on our event website. You can also follow our official social media channels for real-time updates and announcements.

Our event is designed to cater to a wide range of professionals within the biopharmaceutical industry, including researchers, scientists, executives, regulatory experts, and professionals involved in drug development and manufacturing.

The conference will provide a comprehensive learning experience covering various aspects of the dynamic biopharmaceutical industry, ensuring attendees gain valuable insights and knowledge.

Participants can expect to gain insights from industry experts, network with peers, and stay up-to-date with the latest trends and innovations in biopharmaceuticals.

To register for the event, please visit our registration page on our website. You’ll find detailed instructions and options for registration, including pricing and deadlines.

We welcome presentation submissions. If you’re interested in speaking at the event, please visit our “Call for Speakers” page on our website for submission guidelines and deadlines.

Yes, we offer sponsorship and exhibition opportunities for businesses and organizations. Please visit our “Sponsorship Opportunities” page on our website for more information.

We are committed to ensuring the safety and well-being of all attendees. We will implement rigorous safety measures in line with local health guidelines and regulations. Specific safety measures will be communicated closer to the event date to ensure they align with the most up-to-date health recommendations. Rest assured, your safety is our priority.

Yes, we have networking sessions, workshops, and social events scheduled throughout the event to facilitate connections and collaborations among attendees.

Yes, we have a cancellation and refund policy in place. Please refer to our “Cancellation Policy” on our website for details on how to request a refund if you are unable to attend.

THANK YOU TO OUR SUPPORTING PARTNERS

PAST SPONSORS

ADVISORY BOARD

John Power

Senior Director,

BioNTech SE

Australia

Nikolai Petrovsky

Chairman & Research Director

Vaxine Pty Ltd

Australia

2025

SPEAKERS

Featuring esteemed voices from the biopharmaceutical sector. Our selected experts will share insights on the latest trends, challenges, and developments in this dynamic field. Engage in unique discussions, learn about cutting-edge scientific discoveries, and explore the future of biopharmaceuticals with these influential thought leaders. Don't miss this chance to broaden your understanding of this ever-evolving industry.

Silviu Itescu

Chief Executive Officer

Mesoblast

Australia

Carolyn Tucek-Szabo

Senior Director, Global Regulatory Science Lead – Australia/NZ, Policy & Liaison – Southeast Asia,

Moderna

Australia

Cheng-Yi Jerry Kuo

Vice General Manager,

UWELL BioPharma

Taiwan

Chris Alma

Director, External Innovation Biopharmaceutical Product Development, R&D

CSL Limited

Australia

Chunlin Xin

Vice President

CanSino Biologics Inc.

China

Craig Newton

Executive Director & Founder

VivaZome Therapeutics

David Winkler

Professor of Biochemistry and Chemistry

La Trobe University

Australia

Deborah Rathjen

Chief Executive Officer

Carina Biotech

Australia

Ebony Fietz

Drug Development Manager

Currus Biologics

Australia

George Vuckovic

Assistant Secretary, Scientific Evaluation Branch

Therapeutic Goods Administration

Australia

Gisela Mautner

Chief Executive Officer and Managing Director

Noxopharm

Australia

Graham Henry

Associate Director Nonclinical & CMC

Starpharma

Australia

Gregory Troiano

Chief Manufacturing Officer

Sanofi

USA

Ian Nisbet

Chief Operating Officer

Cartherics

Australia

Ilya Vensky

Co-founder and Chief Executive Officer

Helico Bio

New Zealand

Jamie Triccas

Deputy Director

University of Sydney

Australia

Jane Oliaro

Chief Scientist

Peter MacCallum Cancer Centre

Australia

Jennifer Short

Director

Monash Centre for Advanced mRNA Medicines Manufacturing and Workforce Training

Australia

Jerry Kanellos

Chief Scientific Officer

Immuron

Australia

John Power

Senior Director,

BioNTech SE

Australia

Joshua Ooi

Head, Regulatory T-cell Therapies

Monash University

Australia

Killian Kelly

Chief Executive Officer & Managing Director

Cynata Therapeutics

Australia

Larisa Chisholm

Chief Operating Officer

Denteric,

Australia

Marco Herold

Chief Executive Officer, Olivia Newton-John Cancer Research Institute, Head, School of Cancer Medicine, La Trobe University, Honorary Professorial Fellow

University of Melbourne, NHMRC Investigator,

Australia

Michael Baker

Chief Executive Officer & Managing Director, Arovella Therapeutics, Australia

Nicholas Huntington

Co-founder & CSO at oNKo-Innate, Director of Research, Cancer Immunology

Monash University

Australia

Paul McDonald

Chief Executive Officer

IDT

Australia

Rajiv Khanna

Founder and Chief Scientific Officer, Cyteph, Director,

QIMR Centre for Immunotherapy and Vaccine Development

Australia

Rebecca McQualter

Chief Operating Officer,

Chimeric Therapeutics

Australia

Rebecca Skinner

Director, Research and Industry Development, mRNA Victoria

Government of Victoria

Australia

Richard Berry

Vice President, Biologics & Drug Discovery,

oNKo-innate

Australia

Sarah Fitt

Chief Executive Officer

Pharmaceutical Management Agency (PHARMAC)

New Zealand

Thomas Preiss

Director of Shine-Dalgarno Centre for RNA Innovation, Professor of RNA Biology

The Australian National University

Australia

Tim Oldham

Chief Executive Officer & Managing Director,

Adalta

Australia

Vihandha Wickramasinghe

Head, RNA Biology and Cancer Laboratory

Peter MacCallum Cancer Centre

Australia

Xenia Sango

Chief Executive Officer and Managing Director

Vivazome Therapeutics

Australia

DELEGATE REGISTRATION

Catch the limited super access in time to save BIG!

APAC Biopharma / Academic

SGD 1,895

Limited Special (until 6th December 2024)

*END-USER PRICING IS APPLICABLE TO:

Company Profiles: Biopharma, BIG Pharmas, APAC Academic & Research Institutes in APAC (including ANZ)

Job Profiles: Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations.

NON-APAC Biopharma / Academic

SGD 2,395

Limited Special (until 6th December 2024)

*END-USER PRICING IS APPLICABLE TO:

Company Profiles: Biopharma, BIG Pharmas, Academic & Research Institutes outisde of APAC

Service or Solution Provider / Big Pharma

SGD 3,395

Limited Special (until 6th December 2024)

*SOLUTION PROVIDER PRICING IS APPLICABLE TO:

Company Profile: Technology and Solutions Provider, Asian/International Biopharma, BIG Pharmas, CMO’s, CRO's, Asian Academic/Research Institutes.

Job Profiles: Business Development, Marketing & Sales

DELEGATE REGISTRATION

Catch the limited super access in time to save BIG!

APAC Biopharma / Academic

SGD 1,895

Limited Special (until 6th December 2024)

*END-USER PRICING IS APPLICABLE TO:

Company Profiles: Biopharma, BIG Pharmas, APAC Academic & Research Institutes in APAC (including ANZ)

NON-APAC Biopharma / Academic

SGD 2,395

Limited Special (until 6th December 2024)

*END-USER PRICING IS APPLICABLE TO:

Company Profiles: Biopharma, BIG Pharmas, Academic & Research Institutes outisde of APAC

Service or Solution Provider / Big Pharma

SGD 3,395

Limited Special (until 6th December 2024)

*SOLUTION PROVIDER PRICING IS APPLICABLE TO:

Company Profile: Technology and Solutions Provider, Asian/International Biopharma, BIG Pharmas, CMO’s, CRO's, Asian Academic/Research Institutes.

Job Profiles: Business Development, Marketing & Sales

Add valuable perspectives to your work with a dynamic Poster Presentation

In an attempt to capture the essence of the expanding ANZ Biotech industry, the 3rd ANZ Biologics Festival 2025 brings together thought leaders to discuss current trends, opportunities, and to brainstorm ways to navigate through myriad challenges. 

We welcome you to present your research on the following relevant themes including:

Bioprocessing 4.0: Digitalization, AI, and Machine Learning for Manufacturing Efficiencies
Upstream Processing – Process Optimization & Intensification
Downstream Processing – Purification & Recovery for Better Product Efficiency & Yield
GMP Manufacturing, Analytics & Quality Control
Optimizing Delivery Platforms for Next Gen RNA Therapeutics
CGT Manufacturing Innovations for Safe, Efficient, and Scalable Therapies
Accelerating Vaccine Manufacture with mRNA Technology

We're open to other topic proposals as well! Contact sarmila.silvaraja@imapac.com at the button below to secure a spot for your poster presentation.

FEATURED CONTENT

ABF24: Investing in New Zealand Biopharma

ABF24: Biologics Manufacturing Landscape in Australia

ABF24: Cell & Gene Therapy in ANZ

ABF24 Speaker Interview: Key Trends in the ANZ Biopharma Industry

ABF24: Overview of the Australia Biologics Industry

Quick look at ABF 2024: Australia & NZ Biopharma Industry Map

ABF23 Speaker Interview Part 2: Key Future Trends & Innovations in the Australian Biopharma Industry

ABF23 Speaker Interview: Key Future Trends & Innovations in the Australian Biopharma Industry 2023

Quick Look at ABF 2025: ANZ Biopharma Industry Survey Focus Areas

[NEW] Quick Look at ABF 2025: Australia & NZ Biopharma Industry Map

[NEW] Quick Look at ABF 2025: ANZ CDMO Industry Map

[NEW] 2025 ANZ Biologics Advancements: A Comprehensive Overview

Don't Just Take Our Word For It

HEAR FROM OUR CLIENTS

Very educating and inspiring. I thought that careful thought was put into the topics and time allotted for the presentation

Olivia Newton-John Cancer Research Institute,

The most representative conference I have been to yet in Australia of the challenges and capabilities of Australian biologics, particularly cell and gene therapy. When I saw 'biologics festival', I thought it would focus mainly on therapeutic recombinant proteins and antibodies, but the spread of gene and cell therapy included was worth attending for!

ATMP Sweden,

Greatly appreciated the efforts by the organisers to arrange scheduled meetings with KOLs present at the conference. This was an initiative that I hadn't previously seen take place elsewhere and it allowed for fruitful discussion and engagement between attendees and booth exhibitors.

Bio-Strategy Delivering Technology,